Sign in
CompletedNo phase

Using End-Tidal CO₂ to Help Diagnose and Monitor Pulmonary Embolism

Key facts

Who runs it
Ataturk University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
120 people enrolled
Started
1 Feb 2025
Ended
30 Jul 2025
Type of study
Observational, 4 groups
Treatments tested
  • thrombolytic therapy
Record updated
22 December 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Adults aged 18 years or older Diagnosis of acute pulmonary embolism confirmed by CT pulmonary angiography (for PE groups) Classified as high-risk or intermediate-high-risk pulmonary embolism according to ESC/ERS 2019 guidelines Ability to provide informed consent For healthy control group: no history of cardiopulmonary disease, coagulation disorders, or acute medical illness

Who cannot take part

  • Known chronic respiratory diseases significantly affecting EtCO₂ measurement (e.g., advanced COPD, severe asthma, chronic respiratory failure) Active infection, sepsis, or acute complications of malignancy Prior thrombolytic therapy for pulmonary embolism Anatomical or technical limitations preventing reliable nasal capnography Pregnancy Individuals younger than 18 years Inability or refusal to provide informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pulmonary embolism (PE) can reduce blood flow in the lungs and impair gas exchange, leading to lower end-tidal carbon dioxide (EtCO₂) levels. This prospective observational study aims to evaluate whether EtCO₂ can help identify high-risk and intermediate-high-risk patients and monitor early treatment response, especially during thrombolytic therapy. A total of 120 participants were included: high-risk PE, intermediate-high-risk PE patients who received thrombolysis, intermediate-high-risk PE patients treated only with anticoagulation, and healthy controls.

Read full original descriptionShow less

The study measured EtCO₂ along with oxygen saturation, heart rate, respiratory rate, perfusion index, and radiological obstruction scores. By comparing these parameters at diagnosis and during the first 24 hours, the study seeks to determine whether EtCO₂ can serve as a simple, noninvasive marker of disease severity and early hemodynamic improvement in patients with acute PE.

The 4 groups in the trial

  • Group 1: High-Risk Pulmonary Embolism (Thrombolysis)

    Patients presenting with shock or persistent hypotension and receiving systemic thrombolytic therapy.

    Treatment: thrombolytic therapy

  • Group 2: Intermediate-High-Risk Pulmonary Embolism (Thrombolysis)

    Hemodynamically stable patients with RV dysfunction and elevated biomarkers who required thrombolysis.

    Treatment: thrombolytic therapy

  • Group 3: Intermediate-High-Risk Pulmonary Embolism (Non-Thrombolysis)

    Patients meeting intermediate-high-risk criteria but treated with anticoagulation only.

  • Group 4: Healthy Controls

    Individuals without cardiopulmonary disease and with normal clinical and laboratory findings.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of End-Tidal CO₂ Levels in the Diagnosis and Management of Patients With Pulmonary Embolism
Publications
Record updated
22 December 2025